Shares of Invivo Therapeutics Holdings Corp (NASDAQ:NVIV) traded down 6.8% during mid-day trading on Tuesday . The stock traded as low as $0.77 and last traded at $0.82. 533,922 shares were traded during mid-day trading, an increase of 104% from the average session volume of 261,827 shares. The stock had previously closed at $0.88.

Separately, ValuEngine cut shares of Invivo Therapeutics from a “sell” rating to a “strong sell” rating in a research note on Friday, September 1st.

The company has a current ratio of 5.06, a quick ratio of 5.06 and a debt-to-equity ratio of 0.04.

Invivo Therapeutics (NASDAQ:NVIV) last posted its earnings results on Monday, October 30th. The biotechnology company reported ($0.28) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.22) by ($0.06). analysts expect that Invivo Therapeutics Holdings Corp will post -0.81 EPS for the current year.

Several institutional investors have recently bought and sold shares of the company. Legal & General Group Plc raised its position in shares of Invivo Therapeutics by 4,427.9% during the 2nd quarter. Legal & General Group Plc now owns 503,407 shares of the biotechnology company’s stock valued at $1,359,000 after buying an additional 492,289 shares in the last quarter. Goldman Sachs Group Inc. raised its position in shares of Invivo Therapeutics by 144.5% during the 2nd quarter. Goldman Sachs Group Inc. now owns 167,318 shares of the biotechnology company’s stock valued at $452,000 after buying an additional 98,879 shares in the last quarter. Susquehanna International Group LLP purchased a new stake in shares of Invivo Therapeutics during the 2nd quarter valued at $434,000. Blair William & Co. IL purchased a new stake in shares of Invivo Therapeutics during the 2nd quarter valued at $159,000. Finally, LMR Partners LLP purchased a new stake in shares of Invivo Therapeutics during the 2nd quarter valued at $159,000. Hedge funds and other institutional investors own 12.84% of the company’s stock.

TRADEMARK VIOLATION WARNING: This story was originally published by Watch List News and is the property of of Watch List News. If you are viewing this story on another domain, it was illegally stolen and republished in violation of US and international copyright and trademark legislation. The original version of this story can be read at https://www.watchlistnews.com/invivo-therapeutics-nviv-trading-down-6-8/1776311.html.

Invivo Therapeutics Company Profile

InVivo Therapeutics Holdings Corp., formerly Design Source, Inc, is a research and clinical-stage biomaterials and biotechnology company. The Company is engaged in developing and commercializing biopolymer-scaffolding devices for the treatment of spinal cord injuries (SCI). The Company’s approach to treating acute SCIs is based on its investigational Neuro Spinal Scaffold implant, an investigational bioresorbable polymer scaffold that is designed for implantation at the site of injury within a spinal cord contusion and is intended to treat acute spinal cord injury.

Receive News & Ratings for Invivo Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Invivo Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.